Equities analysts predict that TapImmune Inc. (NASDAQ:MRKR) will report earnings of ($0.12) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for TapImmune’s earnings, with the highest EPS estimate coming in at ($0.10) and the lowest estimate coming in at ($0.14). TapImmune reported earnings per share of ($0.64) during the same quarter last year, which would suggest a positive year-over-year growth rate of 81.3%. The company is scheduled to report its next earnings results on Friday, March 20th.
According to Zacks, analysts expect that TapImmune will report full year earnings of ($0.48) per share for the current financial year, with EPS estimates ranging from ($0.50) to ($0.46). For the next year, analysts expect that the company will post earnings of ($0.53) per share, with EPS estimates ranging from ($0.66) to ($0.47). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for TapImmune.
TapImmune (NASDAQ:MRKR) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.01.
Several research analysts have recently commented on MRKR shares. Nomura reiterated a “buy” rating and issued a $16.00 target price on shares of TapImmune in a research report on Tuesday, August 13th. Zacks Investment Research downgraded TapImmune from a “hold” rating to a “sell” rating in a research note on Thursday, October 10th. ValuEngine raised TapImmune from a “hold” rating to a “buy” rating in a research note on Wednesday, October 2nd. Piper Jaffray Companies dropped their price objective on TapImmune from $10.00 to $6.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 13th. Finally, Janney Montgomery Scott cut their target price on TapImmune from $15.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, six have given a buy rating and one has given a strong buy rating to the company. TapImmune currently has a consensus rating of “Buy” and an average price target of $10.15.
NASDAQ MRKR traded up $0.17 during mid-day trading on Tuesday, reaching $2.85. 404,300 shares of the company’s stock traded hands, compared to its average volume of 426,369. TapImmune has a 1-year low of $2.61 and a 1-year high of $9.17. The company has a fifty day simple moving average of $4.16 and a 200-day simple moving average of $5.54. The company has a current ratio of 15.83, a quick ratio of 15.83 and a debt-to-equity ratio of 0.01. The company has a market cap of $130.77 million, a price-to-earnings ratio of -1.71 and a beta of 0.16.
Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets.
See Also: How the Dogs of the Dow Strategy Works
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TapImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TapImmune and related companies with MarketBeat.com's FREE daily email newsletter.